The future of precision medicine

By pairing companion imaging agents with small molecule drug conjugates (SMDCs), Endocyte can provide a more accurate picture of a patient’s disease status—and treatment prognosis.  Learn more

Endocyte strives for precision in medicine

Our treatment philosophy is based on precision—targeting the right patient, the right disease, and the right cells.  Learn more


Our SMDCs are designed to precisely deliver potent compounds with selective activation. Each corresponding companion imaging agent can be viewed with nuclear imaging equipment to assist in therapy selection.

Watch our technology at work


Several of our SMDCs and companion imaging agents are currently in clinical trials for treatment of:

  • Prostate cancer
  • Advanced solid tumors

Learn more

* The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.


Potential treatments for advanced solid tumors of prostate and lung cancers are in Ph1 clinical trials.
Our pipeline

Current Pipeline

EC1169 PSMA-Tubulysin*
EC0652 (Prostate Cancer)*
EC20 Etarfolatide (Molecular Imaging)*